Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0005684 (
bladder cancer
)
16,431
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The General Rule for Clinical and Pathological Studies on
Bladder Cancer
(3rd edition) and General Rule for Clinical and Pathological Studies on Renal Pelvic and
Ureteral Cancer
(2nd edition) were integrated, and the General Rule for Clinical and Pathological Studies on Renal Pelvic, Ureteral, and
Bladder Cancer
was published in April 2011. For histopathological diagnosis, a modification in line with the World Health Organization/International Urological Pathology 2004 classification is performed. Urothelial carcinoma is divided into non-invasive urothelial carcinoma and invasive urothelial carcinoma. With respect to the tumor grade classification for non-invasive papillary urothelial carcinoma, a two-grade classification, which is divided into low and high grade, is adopted instead of the three-grade classification adopted in the previous General Rule for Clinical and Pathological Studies. With respect to tumor subtyping for invasive urothelial carcinoma, twelve subtypes are adopted in the latest General Rule for Clinical and Pathological Studies. Subtyping also complies with the WHO/ISUP2004 classification. The handling of urothelial carcinoma with squamous, glandular, or trophoblastic differentiation is modified and they are classified in subtypes. Nine rare subtypes are also added. In the subtype classification, subtypes that are required to be differentiated from benign lesions or malignant tumors, involved in treatment selection, or related to the prognosis are included.
...
PMID:[Urinary tract tumors]. 2515 78